DRG Epidemiology's influenza forecast will answer the following questions:
- Of all people with influenza, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of influenza over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following influenza patient populations:
- Influenza total event rates.
- Influenza total prevalence.
- Total event rates by diagnosis.
Note: Coverage may vary by country and region.
- Mature Markets Data
- Key Findings
- Introduction Graphics
- Event Rate of Influenza per 1,000 Among People of All Ages in 2018 and 2028
- Relative Sizes of the Contributing Factors to the Trend in Events of Influenza over the Next Ten Years
- Analysis of Events of Influenza in 2018 by Diagnosis Status
- Number of Events of Influenza That Will Be Avoided over the 2018-2028 Period Across the Countries Under Study
- Epidemiology Data
- Total Event Rate
- Total Prevalent Cases
- Percentage Diagnosed
- Reference Materials
- Literature Review
- Risk/Protective Factors
Author(s): Devashri Mukherjee, MPH; Lade Ayodele
Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office. Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.
Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.